Bortezomib Gastric Side Effects
Bortezomib commonly causes gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation, occurring in up to 84% of patients, though these are typically mild to moderate in severity. 1
Common Gastrointestinal Adverse Events
Based on registration trials in multiple myeloma, the most frequent gastric/GI side effects with bortezomib-containing regimens include:
- Diarrhea - One of the most common adverse events when bortezomib is combined with panobinostat 2
- Nausea - Frequently reported, particularly in combination regimens 2, 3
- Vomiting - Common but generally manageable 2
- Constipation - Can progress to more serious complications in certain patients 4, 5
The PANORAMA-1 study specifically identified diarrhea (26% grade 3/4), nausea, vomiting, and anorexia as increased adverse events in the panobinostat/bortezomib/dexamethasone arm compared to controls 2.
Severity and Management Context
While gastrointestinal disturbances and fatigue are the most common adverse effects of bortezomib, they are generally manageable with appropriate medical interventions 3, 6. The gastrointestinal toxicity is typically mild to moderate, though it can have a deleterious effect on quality of life and interfere with optimal therapy 6.
Serious Gastrointestinal Complications
Paralytic Ileus - A Critical Concern
Bortezomib can cause severe paralytic ileus, particularly in patients with impaired renal function (GFR <30 mL/min), and this represents a potentially serious gastrointestinal complication 4, 5.
Key risk factors include:
- Reduced renal function (GFR <30 mL/min)
- Electrolyte abnormalities
- Concurrent opiate use
- Intravenous administration route
For patients with GFR <30 mL/min, upfront bortezomib dose reduction to 1 mg/m² intravenously may prevent paralytic ileus without compromising clinical outcomes 4. The ileus typically presents as progressive constipation and regresses promptly with medical management after drug cessation 5.
Route of Administration Impact
Subcutaneous administration of bortezomib has dramatically improved the initial toxicity profile 3. This route modification, along with weekly dosing schedules, has made bortezomib more tolerable while maintaining efficacy. The introduction of subcutaneous administration represents a major advancement in managing bortezomib's side effect profile.
Comparison with Other Proteasome Inhibitors
When compared to carfilzomib, bortezomib shows similar gastrointestinal toxicity profiles 1. However, newer oral proteasome inhibitors like ixazomib and oprozomib continue to report gastrointestinal toxicities, particularly when combined with other agents 1.
Clinical Monitoring Recommendations
Monitor specifically for:
- Progressive constipation that could indicate developing ileus
- Dehydration from diarrhea or vomiting
- Electrolyte abnormalities (particularly in renally impaired patients)
- Need for dose modifications based on severity
Gastrointestinal side effects are expected with bortezomib therapy but are manageable with appropriate medical interventions including antiemetics, antidiarrheals, and attention to hydration and electrolyte balance 6. Early recognition and treatment according to established guidelines has significantly improved outcomes 3.